Nichol Ochsner

Nichol Ochsner serves as the Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics since August 2022, focusing on building the investor relations and communications function for a company dedicated to rare disease therapies. Prior experience includes roles as Executive Vice President at Statera BioPharma, where Nichol established investor relations for a biotech start-up, and Vice President at TherapeuticsMD, facilitating the transition to a commercial organization in women's health. Additional experiences encompass leadership positions at Aralez Pharmaceuticals, Endo International, and various biopharmaceutical companies, all centered on developing and enhancing investor communication strategies. Nichol holds a BA in Pre-Law from West Virginia University.